ADTX

Aditxt Inc
1.55
0.11 (7.64%)
Upgrade to Real-Time
Afterhours (Closed)
1.55
Volume 751,467
Bid Price 1.52
Ask Price 1.55
News -
Day High 1.6481

Low
0.1242

52 Week Range

High
28.49

Day Low 1.4101
Company Name Stock Ticker Symbol Market Type
Aditxt Inc ADTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.11 7.64% 1.55 19:56:44
Open Price Low Price High Price Close Price Prev Close
1.46 1.4101 1.6481 1.515 1.44
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,247 751,467 $ 1.55 $ 1,166,840 - 0.1242 - 28.49
Last Trade Time Type Quantity Stock Price Currency
19:56:44 formt 100 $ 1.55 USD

Period:

Draw Mode:

Aditxt Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.66M 4.30M 4.24M $ 105.03k $ - -112.50 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 29.90%

more financials information »

Aditxt News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ADTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.451.64811.301.39104,7620.106.9%
1 Month1.47991.64811.20011.42181,0600.07014.74%
3 Months1.871.961.001.52168,609-0.32-17.11%
6 Months0.152628.490.12451.534,069,1441.40915.73%
1 Year0.422528.490.12420.94535383,752,7851.13266.86%
3 Years5.2828.490.12421.952,952,398-3.73-70.64%
5 Years5.2828.490.12421.952,952,398-3.73-70.64%

Aditxt Description

Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.